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Abstract
Liver progenitor cells rise as potential critical players in hepatic regeneration but
also carcinogenesis. It is therefore mandatory to define the signals controlling
their activation and expansion. Recently, by using a novel in vitro model of oval
cell lines expressing a mutant tyrosine kinase-inactive form of c-Met we
demonstrated that autocrine c-Met signalling plays an essential role in promoting
oval cell survival. Here, we investigated the significance of the epidermal growth
factor receptor (EGFR) signalling in oval cell proliferation and survival, as well as
a potential functional crosstalk between the c-Met and the EGFR pathways. We
found an autocrine activation of the EGFR-triggered pathway in Metflx/flx and Met-/-
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IIoval cells as judged by constitutive expression of the EGFR ligands,
transforming growth factor-alpha (TGF-α) and heparin-binding EGF like growth
factor (HB-EGF), and activation of EGFR. On the other hand, treatment with
AG1478, a specific inhibitor of EGFR, effectively blocked endogenous and EGF-
induced proliferation, while increased serum withdrawal and transforming growth
factor-beta (TGF-β)-induced apoptosis. These results suggest that constitutively
activated EGFR might promote oval cell proliferation and survival. We found that
hepatocyte growth factor (HGF) does not transactivate EGFR nor EGF
transactivates c-Met. Furthermore, treatment with AG1478 or EGFR gene
silencing did not interfere with HGF-mediated activation of target signals, such as
protein kinase B (AKT/PKB), and extracellular signal-regulated kinases 1/2 (ERK
1/2), nor did it have any effect on HGF-induced proliferative and antiapoptotic
activities in Metflx/flx cells, showing that HGF does not require EGFR activation to
mediate such responses. EGF induced proliferation and survival equally in
Metflx/flx and Met-/- oval cells, proving that EGFR signalling does not depend on c-
Met tyrosine kinase activity. Together, our results provide strong evidence that in
normal, untransformed oval cells, c-Met and EGFR represent critical molecular
players to control proliferation and survival that function independent of one
another.
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The adult progenitor oval cells are among the most popular and best
studied liver stem/progenitor cell populations. These cells constitute a
heterogeneous population that emerge and expand in the liver parenchyma as a
result of chronic liver injury, subsequently differentiate into hepatocytes and are
responsible for the progenitor-dependent liver regeneration [1,2]. Besides their
regenerative potential solid evidence support their involvement in liver cancer
[3,4]. This dual role emphasizes the urge to learn more about these cells.
Particularly important is to put forth efforts to dissect the signalling network
regulating their development, fate and function. An increasing number of factors
and signalling pathways, including growth factors, inflammatory cytokines,
chemokines, and hormones, are being identified and/or postulated as major
regulators of oval cell proliferation, differentiation and homeostasis, picturing a
quite complex and unclear scenario. Among others, the well-known receptor
tyrosine kinase (RTK) signaling systems, HGF/c-Met, and EGF/EGFR (also
known as ErbB1), are certainly interesting targets for experimental studies. Both
signalling pathways have a remarkably pleiotropic nature and share common
intracellular signalling molecules and biological effects, playing fundamental roles
during development and oncogenesis [ 5-8]. The HGF actions, namely
proliferation, survival, motility, and morphogenesis, are driven by ligand binding-
dependent autophosphorylation of c-Met on specific tyrosine residues in the
tyrosine kinase and C-terminal domains, followed by either adapter-mediated or
direct recruitment and activation of multiple signal transducers, including Ras-
ERK 1/2 mitogen activated protein kinases (MAPKs), phosphatidylinositol-3
kinase (PI3K)-AKT, phospholipase C-γ (PLC-γ), p38, and STAT3 [9]. EGF, on the
other hand, binds to and activate the EGFR, which is part of a complex signalling
system that includes up to 15 different ligands, transforming growth factor alpha
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(TGF-α) included, and four transmembrane receptors, ErbB1 (Her1/EGFR),
ErbB-2 (Her2/neu), ErbB-3 (Her3), and ErbB-4 (Her4) [10,11]. Similarly to HGF
pathway, ligand binding results in dimerization and autophosphorylation of the
receptor in tyrosine residues of the cytoplasmic domain. Receptor activation
leads to recruitment of adapter proteins, such as Grb2 and Shc, and subsequent
activation of diverse downstream effectors, most of which are shared between
the Met and ErbB1 pathways, mediating cell proliferation, migration,
differentiation and evasion from apoptosis.
Evidence of a role for both HGF and TGF-α signalling systems in progenitor cell-
mediated regeneration is available in the literature. Indeed, both TGF-α and
HGF, as well as their respective receptors, ErbB1 and c-Met, are transcriptionally
up-regulated during the period of active proliferation and differentiation of
progenitor cells in the rat liver subjected to the 2-acetylaminofluorene/partial
hepatectomy (2-AAF/PH) protocol [12-14]. Furthermore, in vivo infusion with
either EGF or HGF amplifies liver progenitor expansion following liver injury and
decreases cell apoptosis [15]. Recently, using a novel in vitro model of oval cell
lines harboring a genetically inactivated c-met tyrosine kinase, we have
demonstrated that c-Met-supported signalling plays an essential role in
promoting oval cell survival but is dispensable for proliferation [16]. We have also
seen that EGF elicits mitogenic activity in mouse oval cells in vitro. However, the
degree of functional redundancy, cooperation or dependence between these two
signalling pathways in oval cells remains unknown. To this effect, it is well known
that c-Met-signalling is modulated by direct communication with other receptors.
In fact, a direct cross-talk between c-Met and ErbB1 has been proposed in a
variety of cell systems, modulating c-Met-driven downstream signalling and
cellular responses. For instance, mitogenic activity of HGF on rat primary
hepatocytes has been reported to be dependent on TGF-α synthesis and ErbB1
activation [17,18]. In addition, cross-talk between these two RTKs appears to
have significant implications in oncogenesis, where aberrant activation of one
RTK may lead to overexpression and activation of the other [19].
On this basis, we undertook the present study to evaluate the significance
of the EGFR signalling pathway on oval cell proliferation and survival and to
explore whether a direct crosstalk between EGFR and c-Met exists in these cells
and its contribution, if any, to c-Met signalling. Using a combined genetic and
chemical approach, we demonstrate for the first time that an EGFR-mediated
autocrine signalling promotes oval cell proliferation and survival in vitro, being c-
Met tyrosine kinase dispensable for EGFR-triggered actions. Furthermore,
chemical inhibition of EGFR kinase activation does not prevent HGF-induced
DNA synthesis and protection against apoptosis in mouse oval cells. Together,
our data provide direct evidence that, although both c-Met and EGFR-driven
signals support oval cell growth and survival, their respective tyrosine kinase
activities are not mutually dependent upon one another.
2. Material and Methods
2.1. Reagents and antibodies
Mouse recombinant HGF was purchased from R&D Systems
(Minneapolis, MN). EGF was from Serono Laboratories (Madrid, Spain). Human
recombinant TGF-β and AG1478 were from Calbiochem (La Jolla, CA).
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and
trypsin-EDTA were from Gibco-Invitrogen (Barcelona, Spain). Penicillin,
streptomycin, HEPES, bovine serum albumin (fraction V, fatty-acid free),
propidium iodide, DNA oligos, and all buffer reagents were from Sigma-Aldrich
(Tres Cantos, Madrid, Spain). RNeasy Kit was from Qiagen (Valencia, CA).
SuperScript III RNase H Reverse Transcriptase was from Invitrogen. Oligo-dT
was from Roche Diagnostics (Sant Cugat del Valles, Barcelona, Spain). [3H]-
thymidine (25.0 Ci/mmol), HRP-conjugated secondary antibody, and ECL
reagent, were from GE Healthcare Europe (Barcelona, Spain). Caspase-3
substrate was obtained from PharMingen (San Diego, CA). The rabbit polyclonal
antibodies: anti- EGFR (CS-2232), anti-phospho EGFR (CS-2236), anti-STAT3
(CS-9132), anti-phospho STAT3 (Ser 727) (CS-9134), anti-AKT (CS-9272), anti-
phospho-AKT (Ser 473) (CS-9271), anti-p44/p42 MAPK (Erk 1/2) (CS-9102),
anti-phospho-p44/p42 MAPK (Erk 1/2) (Thr202/Tyr204) (CS-9101), were
purchased from Cell Signaling (Beverly, MA). A rabbit polyclonal against c-Met
(sc-162) was from Santa Cruz Biotechnology, Inc., (Paso Robles, CA). A mouse
monoclonal antibody against phospho-tyrosine (recombinant clone 4G10) was
from Upstate Biotechnology, Inc., (Lake Placid, NY) and mouse monoclonal anti-
β-actin (clone AC-15) antibody was from Sigma-Aldrich. Protein A-agarose beads
were from Roche and anti-mouse IgG (whole molecule)-agarose was from
Sigma.
2.2. Cell Lines and Culture Conditions
Metflx/flx and Met-/- oval cell lines were generated as described previously
[16]. Cells were routinely maintained in DMEM supplemented with 10%FBS in a
humidified incubator at 37°C and a 5% CO2 atmosphere. Medium was replaced
every three days, and cells were harvested at 80% to 90% confluence using
trypsin-EDTA and replated at 1:10 dilution for maintenance. After an overnight
attachment period, medium was replaced by serum-free DMEM. Cells were
maintained in serum-free medium for 4-12h prior to treatment with growth factors.
HGF was added before the TGF-β treatment for a minimum of 6 hours. AG1478
was added 30 min before addition of growth factors.
2.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis
Total cellular RNA was isolated using the RNeasy Kit (Qiagen, Valencia,
CA). RNA yield and purity were analyzed using a spectrophotometer (UV-visible
recording spectrophotometer Specord 205, AnalytikJena). Three µg total RNA
was reverse-transcribed into complementary DNA using SuperScript III RNase H
Reverse Transcriptase and oligo-dT as a primer. The PCR primers were as
follows: hb-egf (forward GACCCATGCCTCAGGAAATA, reverse
TGAGAAGTCCCACGATGACA), tgf-α  (forward TGGTGCAGGAAGAGAAGC,
reverse TGACAGCAGTGGATCAGC), β-actin (forward
ATGCCATCCTGCGTCTGGACCTGG, reverse
GCATTTGCGGTGCACGATGGAGGG).
Cycling parameters were: denaturation at 94°C for 1 minute, annealing
temperatures of 57 to 65°C for 1 minute, and extension at 72°C for 1 minute (30
to 35 cycles of amplification). Amplified products were subjected to
electrophoresis in 1.2 to 1.5% agarose gels and stained with ethidium bromide
for visualization.
2.4. DNA Synthesis Analysis
Cells were plated at a density of 17,500 cells/sq cm in DMEM with
10%FBS. The following day, cells were incubated for 48 hours in serum-free
medium with or without growth factors, epidermal growth factor (20 ng/ml) or
HGF (40 ng/ml). Incorporation of 3H-thymidine during the last 40 hours of culture
was measured in trichloroacetic acid precipitable material following a previously
described protocol [20].
2.5. Measurement of Apoptotic Index
The following day after cell seeding, the complete medium was replaced
by serum-free DMEM with or without exogenous factors and/or inhibitor, AG1478
(5 µM), TGF-β (1 ng/ml), EGF (20 ng/ml), HGF (40 ng/ml). Cells undergoing
apoptosis were scored under inverted fluorescence microscope (Eclipse TE300,
Nikon) at high magnification (x60) following standard morphological criteria, such
as chromatin condensation, nuclear pyknosis, and nuclear fragmentation. A
cluster of closely packed apoptotic bodies was scored as one. Cells were stained
with propidium iodide as described [21] and apoptotic indices were calculated
after counting a minimum of 1000 cells per treatment in a blinded manner.
2.6. Measurement of Caspase-3-Like Enzymatic Activity
A fluorometric assay in the presence of Ac-DEVD-AMC as fluorogenic
Caspase-3 substrate was used following a previously described procedure [22].
Cleavage of the substrate was monitored in a Microplate Fluorescence Reader
FL600 (Bio-Tek) (excitation, 380 nm; emission, 440 nm). A unit of caspase
activity is the amount of enzyme that will lead to a one unit increase in the
fluorescence intensity. Protein concentration was estimated and results are
expressed as units of activity per microgram of protein.
2.7. Immunoprecipitation and Immunoblotting
For phospho-EGFR immunoprecipitation, cells were lysed in a buffer
containing 50 mM Tris, pH7.5; 150 mM sodium chloride; 1% NP-40; 5 mM EGTA;
5 mM EDTA, supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml
aprotinin and leupeptin, and 1 mM sodium orthovanadate. 500-1000 µg of protein
was incubated overnight at 4ºC with antibody against phospho-tyrosine. The
following day, complexes were precipitated for 1h at 4ºC with anti-mouse IgG
whole molecule-agarose antibody. Pellets were washed three times with the lysis
buffer and heated for 5 min at 95ºC in Laemmli sample buffer for western blot
analysis using an antibody against EGFR.
For Met immunoprecipitation, total cell extracts prepared with a lysis buffer
containing 10 mM Tris, pH 7.4; 150 mM sodium chloride; 1% NP-40; 1% sodium
deoxycholate; 0.1% SDS; 2 mM EDTA; plus protease and phosphatase inhibitors
(as described above), were immunoprecipitated using a rabbit polyclonal anti-c-
Met antibody and protein A-agarose beads. The solubilized immunoprecipitates
were processed as above and analyzed by Western blotting using an anti-
phosphotyrosine antibody.
For standard western blotting (without immunoprecipitation), total cell
extracts were prepared in modified RIPA buffer: 30 mM Tris pH 7.5; 150 mM
sodium chloride; 1% NP40; 0.5% sodium deoxycholate; 0.1% SDS; 5 mM EDTA
supplemented with 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin and
leupeptin; 1 mM sodium orthovanadate. 40 to 80 µg of protein were separated in
10-12% acrylamide sodium dodecyl sulfate-polyacrylamide electrophoresis gels
and blotted to Immobilon-P membranes (Millipore, Bedford, MA). Membranes
were probed with the primary antibodies diluted 1:500 to 1:1000 in Tris-buffered
saline containing 0.1% Tween 20 and 0.5% non-fat dried milk or 0.5% bovine
serum albumin according to manufacturer’s instructions. Detection was done
using the enhanced chemiluminescence method and autoradiography.
2.8. Statistical Analysis
Statistical analysis was performed by Student’s t-test analysis. The
differences were assumed significant at P <0.05.
3. Results
3.1. Oval cells express EGFR ligands and show constitutive activation of EGFR
Aiming to understand the relevance of EGFR signalling in adult liver
progenitor oval cells and to explore a potential cross-talk between EGFR and Met
in these cells, Metflx/flx and Met-/- oval cells were first investigated for the
expression of EGFR ligands transcripts using semiquantitative RT-PCR. For this,
cells were cultured in complete medium (10%FBS) or serum-free medium for 24
hours and total RNA was used for detecting hb-egf and tgf-α mRNAs. Transcripts
encoding these two ligands were detected both in Metflx/flx and Met-/- oval cells, in
the presence or absence of serum, demonstrating a constitutive expression of
the EGFR ligands hb-egf and tgf-α in mouse oval cells (Fig. 1A). Previous
experiments had evidenced that Metflx/flx and Met-/- oval cells express EGFR,
since both cell lines respond to EGF with an increase in cell proliferation [16].
Based on the simultaneous expression of EGFR and EGFR ligands, we
hypothesized that an autocrine EGFR-mediated signalling could be active in oval
cells. To test this idea, we analyzed the phosphorylation state of EGFR in Metflx/flx
and Met-/- oval cells in basal conditions (in the absence of serum and exogenous
stimuli) and compared to that in EGF-stimulated cells. After immunoprecipitation
of cell lysates with anti-phosphotyrosine antibody and subsequent immunoblot
analysis with anti-EGFR antibody, a prominent 170 kDa tyrosine-phosphorylated
band corresponding to the EGFR was detected in oval cells treated for 10 min
with EGF (20 ng/ml). Although less intense, a 170 kDa band was also seen in
untreated serum-starved Metflx/flx and Met-/- oval cells (Fig. 1B), thus showing
endogenous phosphorylation of EGFR in both oval cell lines. These results
provide strong evidence for an autocrine EGFR signalling in mouse oval cells.
3.2. EGFR-mediated signalling promotes proliferation and survival in mouse oval
cells
EGFR ligands are well-known inducers of proliferation and survival in
hepatocytes [23,24]. In vivo evidences suggest similar roles for the EGFR
ligands/EGFR axis in liver progenitor cells [13,15]. Therefore, to evaluate the
functional relevance of the autocrine EGFR signalling in Metflx/flx and Met-/- oval
cells, we next examined the effect of inhibiting EGFR activity on oval cell
proliferation and survival. Proliferation was assessed by measuring the rate of
oval cells DNA synthesis by tritiated-thymidine incorporation into DNA. As shown
in Fig. 2A, EGF is a strong mitogen in both Metflx/flx and Met-/- oval cells, causing
a 4-6 fold increase in the proliferation rate. The effect of EGF was completely
abolished when EGFR activity was inhibited by treatment with the EGFR specific
inhibitor, AG1478 (5 µM). Interestingly, basal oval cell DNA synthesis was also
drastically reduced in the presence of the inhibitor, indicating that both basal and
EGF-induced oval cell DNA synthesis in vitro depend on the tyrosine kinase
activity of EGFR. Furthermore, AG1478 induced an increase in the apoptosis
rate of serum-deprived Metflx/flx and Met-/- oval cells (Fig. 2B). The total apoptotic
index under AG1478 treatment was mild-to-moderate but the observed increase
over untreated cells was statistically significant. Particularly remarkable was the
significantly higher apoptotic index in AG1478-treated Met-/- cells as compared to
Metflx/flx cells. Consistent with an increase in the apoptosis rate, AG1478-treated
oval cells showed elevated caspase-3 activity over control untreated cells.
Moreover, accordingly to apoptotic index data, the AG1478-induced increase in
caspase-3 activity was significantly stronger and more persistent in Met-/- cells
(Fig. 2C). These results suggest that an autocrine signalling through EGFR
operates in oval cells to promote cell proliferation and survival. Our data also
suggest that in the absence of c-Met-driven survival signals oval cells become
more dependent on the pro-survival activity of EGFR.
Previously, we have reported that TGF-β induces apoptosis in oval cells
and that lack of c-Met tyrosine kinase activity makes oval cells more sensitive to
the pro-apoptotic effects of this cytokine [16]. To gain greater insights into the
EGFR-driven antiapoptotic activity, we also tested the effect of AG1478 on TGF-
β-treated oval cells. As seen in fig. 2D, AG1478 significantly amplified TGF-β-
induced apoptosis both in Metflx/flx and Met-/- cells, reaching average apoptotic
indices of 35.6±9.3 and 48.2±12%, respectively, after 48 hours of treatment. It is
worth noting that apoptotic indices consistently reached higher values in Met-/-
oval cells. However, differences between Metflx/flx and Met-/- cells did not reach
statistical significance. Regardless of this, and similar to what we have previously
described in hepatocytes and hepatoma cells [25,26], our data support a critical
role for EGFR in protecting against TGF-β-induced apoptosis in oval cells.
3.3. Lack of Met-EGFR signalling cross-activation in mouse oval cells.
We have shown that both Met and EGFR trigger proliferative and anti-
apoptotic signals in oval cells. Increasing evidence in the literature has reported
crosstalk between c-Met and EGFR. The mechanistic nature of such crosstalk is
very complex, and depends on the particular cell system and the
physiological/pathological context. Thus, it might occur directly or indirectly,
involve different levels of interaction, and can have additive or antagonistic
effects [19]. On this basis, we investigated whether EGFR may play a role in c-
Met-dependent signalling in oval cells and vice versa.
Since EGFR is known to transactivate c-Met [27-29], and HGF can
activate EGFR [30], we first examined whether the exposure to exogenous HGF
increases phosphorylation of EGFR. Cells were treated for 10 min with 40 ng/ml
of HGF and then harvested to analyze phosphorylation and activation of EGFR
and downstream signalling molecules, such as AKT and ERK 1/2. Cells treated
for 10 min with 20 ng/ml of EGF were used as positive control for EGFR
activation. Addition of EGF, but not HGF, resulted in EGFR phosphorylation both
in Metflx/flx and Met-/- cells (Fig. 3A). However, phosphorylated AKT and ERK1/2
were observed under both treatments, which is consistent with the fact that these
kinases are downstream signalling molecules shared by EGFR and c-Met. The
activation of AKT and ERK 1/2 by HGF occurred in Metflx/flx, but not Met-/-, oval
cells. Cumulatively, these results show that EGF and HGF trigger common
signalling pathways in mouse oval cells, through their respective receptors,
EGFR and Met. It should be noted that although levels of phosphorylated EGFR
appeared higher in Metflx/flx cells, a thorough analysis revealed no consistent
differential EGFR phosphorylation pattern. Moreover, the levels of
phosphorylated EGFR did not correlate with the levels of activation of target
signalling molecules, AKT and ERK 1/2, thus discarding the possibility of a
diminished EGFR-triggered signalling in Met-/- oval cells due to the absence of c-
Met tyrosine kinase activity.
To analyze whether EGF was able to drive c-Met activation, cells were treated in
the same way and subsequently c-Met phosphorylation was detected by
immunoprecipitation from cell lysates with anti-c-Met antibody, followed by
western blot analysis with anti-phosphotyrosine antibody. Phosphorylated c-Met
was readily detected in Metflx/flx cells treated with HGF, but not with EGF (Fig.
3B). As expected, no phosphorylated c-Met was seen in Met-/- cells, regardless of
the treatment used.
Altogether, these observations demonstrate that neither HGF induces EGFR
tyrosine phosphorylation nor EGF phosphorylates c-Met, in mouse oval cells.
Our finding that EGFR signals through AKT and ERK 1/2 in oval cells with or
without Met kinase activity, Metflx/flx and Met-/-, respectively (Fig. 3A), coupled with
the fact that the EGF-induced mitogenic effect in Met-/- oval cell is
indistinguishable from that induced in Metflx/flx cells (Fig. 2A) provide solid
evidence that EGF-triggered signalling and biological responses in oval cells do
not require a functional Met tyrosine kinase. To further validate this hypothesis,
we ought to compare the anti-apoptotic activity of EGF against TGF-β in our
cells. As shown in Fig. 4, EGF was able to completely abolish TGF-β-induced
apoptosis in Metflx/flx as well as Met-/- oval cells. In conclusion, our analyses show
that Met tyrosine kinase is dispensable for EGFR-driven proliferation and survival
in mouse oval cells.
3.4. HGF-induced mitogenic and survival activities in mouse oval cells are
independent from EGFR kinase activity.
Although bidirectional cross-talk between Met and EGFR might occur, a
role for EGFR in Met-mediated signalling seems to be more established,
particularly in hepatic cells [17,18,28]. Hence, we next tested the consequences
of inhibiting the EGFR kinase on HGF-driven signalling.  As seen in Fig. 5A,
activation of Akt, ERK 1/2, and STAT3 by HGF in Metflx/flx oval cells was not
reduced nor inhibited in the presence of AG1478, whereas it completely
abolished activation of EGFR downstream signalling pathways (AKT, ERK 1/2) in
EGF-stimulated cells (Fig. 5B). These results indicate that AKT and ERK 1/2
signalling downstream of c-Met activation occurs independently of EGFR
activation.
We have previously reported that HGF elicits mitogenic and anti-apoptotic
activities in mouse oval cells [16]. To unequivocally assess whether or not EGFR
kinase contributes to HGF-mediated activities in oval cells, we chose to analyze
the effects of the inhibitor AG1478 on HGF-driven proliferation and survival. If a
total or partial dependence on EGFR activity existed, an inhibition or decrease of
those effects should be expected upon inhibition of EGFR. Instead, HGF-elicited
increase in DNA synthesis was preserved in spite of EGFR inhibition (Fig. 6A).
EGF-treated cells were used as positive control for the specificity and efficacy of
the inhibitor. AG1478 completely prevented EGF-mediated enhancement in DNA
synthesis as anticipated.
 A similar approach was used for the analysis of the effect of EGFR
inhibition on HGF-mediated protection against TGF-β-induced apoptosis. We
have previously described that addition of exogenous HGF resulted in an
approximate 50% decrease in the TGF-β-induced apoptosis [16]. The same
decrease was observed when AG1478 was present (Fig. 6B), demonstrating that
the EGFR kinase is not required for the HGF pro-survival activity in oval cells.
As an additional approach to further confirm these results we silenced the
expression of EGFR with siRNAs. As shown in supplementary figure 1A, a high
silencing efficiency was reached based on the almost complete disappearance of
the EGFR protein. Consistent with the AG1478 data, EGFR knockdown did not
prevent HGF-induced activation of target signals, ERK1/2 and AKT (suppl.
Fig.1B). Furthermore, neither the HGF-mediated increase in DNA synthesis nor
the protection against TGF-β-induced apoptosis, were affected by EGFR
silencing (suppl. Fig. 1C,D).
These studies together demonstrate that c-Met and EGFR promote
proliferation and survival of mouse oval cells independent of one another.
4. Discussion
The signalling pathways that control oval cell biology are only poorly
understood. In this study we have directly approached the relevance of EGFR-
mediated signaling for mouse oval cell proliferation and survival in vitro. In
addition to this, we have analyzed whether a functional dependency exists
between the two RTKs, EGFR and c-Met, for controlling such responses. Our
results show an autocrine EGFR activation in mouse oval cells that promotes
proliferation and survival. Furthermore, we demonstrate that neither EGFR
requires c-Met activity nor c-Met requires EGFR activity to elicit their mitogenic
and anti-apoptotic functions in oval cells.
It is well known that the EGFR and its ligands play a critical role in the
proliferative response accompanying liver regeneration after partial hepatectomy
[23]. In fact, mice lacking EGFR showed a delay in liver regeneration due to a
reduced hepatocyte proliferation and cell cycle progression [31]. In contrast,
scarce data is available in the literature regarding EGFR signalling in progenitor-
mediated liver regeneration. The fact that infusion of TGF-α increases oval cell
proliferation after 2-AAF/PH protocol [15] suggested that EGFR signalling is also
an important regulator of liver progenitor cells proliferation in a regenerative
context, but for now, the impact of deleting EGFR signalling in liver regeneration
from oval progenitor cells remains undefined. Interestingly, TGF-α transcripts are
undetectable or very low in normal liver or non-replicating hepatocytes, but are
up-regulated in hepatocytes during partial hepatectomy and toxic injury [32,33]
as well as in proliferating oval cells and basophilic foci of hepatocytes in
regenerating liver induced by a modified Solt-Farber protocol [12], providing
indirect evidence for the implication of an autocrine mechanism. Here, using in
vitro approaches we present the first direct evidence of the autocrine action of
EGFR ligands in non-tumorigenic oval cells. This is supported by constitutive
expression of EGFR ligands (Fig. 1A) and activation of EGFR (Fig. 1B); as well
as a decrease in basal proliferation rate and increased apoptosis upon inhibition
of EGFR kinase (Fig. 2). Remarkably, the EGFR inhibitor almost completely
inhibits endogenous oval cell proliferation (Fig. 2A), resembling the response
seen in hepatoma cells [34]. Similar results have also been reported in adult rat
hepatocytes [18] using PKI166, a dual EGFR/ErbB2 inhibitor, although the
inhibitory effect was not as strong as that observed in oval cells using AG1478.
More importantly, the presence of c-Met tyrosine kinase cannot override the
potent inhibitory effect of AG1478 on cell proliferation (Fig. 2A). This, together
with our previous results showing that lack of c-Met tyrosine kinase activity has
no effect on oval cell proliferation [16], strongly suggest a major role for EGFR in
regulation of oval cell proliferation.
It is well known that EGFR-dependent signalling integrates proliferative
and survival signals in hepatocytes. Indeed, we and others have previously
reported that EGF induces proliferation [20] and protects hepatocytes from
various apoptotic insults, including TGF-β, Fas, and deoxycholic acid [25,35,36].
Furthermore, EGFR is activated and required for TGF-β-induction of anti-
apoptotic signals, such as AKT [22], constituting a part of the mechanism
induced by TGF-β to confer resistance to apoptosis in fetal hepatocytes after an
EMT process [37]. Consistent with these data, we see an increased apoptotic
index under serum deprivation as well as TGF-β treatment in the presence of
AG1478 (Fig. 2B-D). We have not explored in detail the mechanisms involved in
the EGFR autocrine antiapoptotic signalling in oval cells. However, we see a
notable decrease in TGF-α mRNA levels under AG1478 treatment (data not
shown), which indicates that EGFR kinase activity is required for the induction of
the expression of EGFR ligands, thus activating a pro-survival amplifying loop.
On the other hand, the lower apoptosis levels displayed by serum-deprived
Metflx/flx cells in the presence of AG1478 are consistent with an active Met-
dependent autocrine survival signalling in Metflx/flx oval cells [16], and serve as an
additional proof for the capacity of c-Met signalling to restrain the apoptotic
response in oval cells. It should be pointed out that EGFR silencing did not result
in an amplification of the apoptotic response in oval cells (suppl. Fig.1D). This
result was not at all surprising since we have recently described that AG1478 has
broader effects than EGFR silencing on apoptosis in hepatocellular carcinoma
cells [38]. These observations make clear that AG1478 might have both EGFR-
dependent and independent effects, and leave the door open to future studies to
explore additional targets, including other members of the ErbB receptor family.
Taken altogether, our results constitute compelling evidence for a regulation of
oval cell growth and survival by autocrine growth factors, i.e., HGF and EGFR
ligands. At the same time, they highlight non-redundant roles for autocrine EGFR
and c-Met signalling in oval cell proliferation and survival. While EGFR seems to
be more important for driving proliferation, both RTKs might cooperate to protect
cells against apoptotic insults. Nonetheless, c-Met appears to have some unique
effects on promoting cell survival, which would explain why EGFR is not able to
compensate for c-Met loss.
It is of particular interest that EGF is able to protect against TGF-β-induced
apoptosis regardless the presence or absence of a functional c-Met (Fig. 4).
These data indirectly suggests that EGFR-mediated antiapoptotic signalling
operating in oval cells is independent of Met tyrosine kinase activity. The
communication between Met and EGFR and its functional consequences has
been a major subject of debate during many years. Different mechanisms, alone
or in combination, might mediate direct and indirect crosstalk between these
receptor systems. Such mechanisms include physical interaction between
receptors, ligand-mediated transactivation of the receptors, or induction of ligand
gene transcription [19]. In this study, we have tested whether one or several of
these mechanisms operate in oval cells. Results demonstrate that in oval cells
EGFR is activated by EGF, but not HGF, and c-Met is activated by HGF, but not
EGF (Figure 3), which indicates that no ligand-induced transphosphorylation
between c-Met and EGFR occurs. Moreover, inhibition of EGFR activity by
AG1478 treatment or siRNA-mediated EGFR gene silencing has no effect on
ligand-mediated activation of c-Met downstream targets (Fig.5A and suppl.
Fig.1B). Our results are in agreement with data from primary rat hepatocytes
showing that only HGF but not EGF drives c-Met phosphorylation and EGFR
inhibition does not affect HGF-induced c-Met activation [18]. However, differently
from oval cells, either inhibition of EGFR activity [18] or TGF-α synthesis and
activity [17], block the mitogenic effect of HGF on hepatocytes. This, together
with results indicating the capability of HGF to induce TGF-α mRNA transcription
in HepG2 cells [39], suggests that in normal and tumorigenic hepatocytes, HGF
might promote hepatocyte proliferation in an EGFR-dependent manner through
the production of EGFR ligands. A similar transcription-dependent crosstalk
between c-Met and EGFR has been established in several cell types, including
malignant and untransformed cells [30,40], where it is required for induction of
cell proliferation or motility. We prove here that this mechanism does not work in
oval cells, where EGFR is not required for HGF/c-Met-driven signalling (Fig.5A
and suppl. Fig.1B) and mitogenic and anti-apoptotic activities (Fig. 6A,B and
suppl. Fig.1C,D), hence discarding any role for EGFR in the HGF-triggered
effects in oval cells. Altogether, these findings make it clear that communication
between EGFR and c-Met and the mechanisms involved are cell and context
dependent, revealing an enormous plasticity of the cell signalling mechanisms,
which allow cells to adjust to the continuously variable environment. Additionally,
in spite of the apparent prevalent role in oncogenesis, cross-talk between c-Met
and EGFR might also be relevant in some particular non-tumorigenic contexts,
e.g. development, tissue homeostasis and regeneration, where crosstalk within
signalling networks might be crucial for the control of proliferation, survival, and
motility processes, and ultimately for successful completion of any of these
programs. Why HGF does not use EGFR as part of the signalling cascade
activated in oval cells to induce cell proliferation or survival remains unclear.
Certainly, communication between the two RTKs could be beneficial as it
provides additional signalling platforms to control cell response and fate. It might
be that EGFR had a less central role in oval cell regulation than it has on
hepatocytes and other epithelial cells. Likewise, c-Met might have other preferred
partners, among the multiple membrane proteins with whom it can interact [19].
From a different perspective, the fact that HGF does not require EGFR kinase
activation to promote its actions can be seen as a sign of a more dominant role
for c-Met in oval cells, which is able to trigger cell responses regardless of
whether EGFR is functional or not.
It is plausible that the EGFR-Met crosstalk could gain relevance in
transformed oval cells, where crosstalk might be important to amplify RTK
signaling and contribute to cell transformation. Accordingly, overexpression of
TGF-α in normal rat liver epithelial cells (RLEC) and tumor clones derived from
them results in phosphorylation of c-Met in the absence of HGF [41]. Similarly,
HCC and other tumor cell lines show constitutively phosphorylated c-Met, effect
that is inhibited by neutralizing antibodies against TGF-α and/or EGFR or by
treatment with AG1478 [28]. However, differently from oval cell lines, constitutive
phosphorylation of Met in hepatocellular carcinoma (HCC) cells is not associated
to the expression of the HGF transcript, but more likely to autocrine TGF-α.
These and other studies establish a direct link between oval cell malignancy and
autocrine signalling, signalling crosstalks, and alteration in growth factor
responsiveness. Both HGF and TGF-α autocrine loops have been identified in
transformed rat oval cells and close relatives, and proven to confer tumorigenic
properties [42-44]. Conversely, recent studies performed using the non-
tumorigenic oval cell line LE6 and retroviral-mediated expression of MYC, TGFα
or the combination of both, have demonstrated that only MYC and MYC/TGFα-
transfected oval cells, but not oval cells expressing TGFα alone, develop tumors
when injected into nude mice [45]. Furthermore, our results have also shown that
non-tumorigenic oval cells display autocrine activation of c-Met [16] and EGFR
tyrosine kinases (Fig. 1B). Therefore, it seems that TGFα/EGFR or HGF/c-Met
autocrine loops are not generally sufficient to promote oval cell transformation. It
might certainly be one common feature in transformed immature epithelial cells
and contribute to support autocrine growth of liver tumor cells but neoplastic
transformation requires additional critical partners.
In conclusion, EGFR and c-Met drive common biological responses, such
as mitogenesis and protection against apoptosis, in oval cells. However, results
suggest distinct non-overlapping roles for EGFR and c-Met. Thus, in spite of the
capacity of both receptors to induce mitogenic and survival signals, EGFR seems
to be a more efficient and relevant mitogenic signal than c-Met, whereas c-Met
appears to have some unique and prevalent effects as a pro-survival signal. In
addition, although our results do not at all rule out that EGFR and c-Met can act
cooperatively and/or coordinately to promote these activities in specific contexts,
they show that neither of the two RTKs depends on each other activity. Important
questions remain open concerning whether EGFR-c-Met crosstalk would be
activated upon transformation of oval cells and contribute to HCC development
or progression. Certainly, the lack of RTKs promiscuity could very well constitute
a safekeeper mechanism to protect oval cells from malignant conversion.
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Figure legends
Figure 1. Constitutive expression of EGFR ligands and activation of EGFR in
mouse Metflx/flx and Met-/- oval cell lines. (A) EGFR ligands mRNA expression
was analyzed by RT-PCR in oval cells cultured for 24h in the absence or
presence of 10% FBS. β-actin was used for normalization. RT-: no reverse
transcription. (B) Oval cells were serum-starved for 12h and then treated with
EGF (20 ng/ml) for 5 min. Cell lysates were immunoprecipitated with anti-
phosphotyrosine antibody and blotted with anti-EGFR antibody. Neg.: negative
control (no primary antibody). Sup.: positive control (IP input), supernatants
collected after immunoprecipitation from the same lysates.
Figure 2. Effect of EGFR inhibition with AG1478 on mouse Metflx/flx and Met-/-
oval cells proliferation and apoptosis. (A) DNA synthesis as determined by
thymidine incorporation in oval cells cultured for 48h in the absence or presence
of EGF (20 ng/ml) pretreated or not with AG1478 (5 µM) for 30 min. Data are
mean±SEM of three independent experiments. *P < 0.05. ***P < 0.001. (B)
Apoptotic index in oval cells treated with 5 µM AG1478 for the indicated times.
Apoptotic nuclei were visualized and counted after PI staining under a
fluorescence microscope in a blinded manner. A minimum of 1000 cells was
counted per dish. Data are mean±SEM of six independent experiments. *P <
0.05. (C) Kinetics of caspase-3 activity in oval cells treated with 5 µM AG1478.
Data are mean±SEM of six independent experiments. *P < 0.05. **P < 0.01. (D)
Apoptotic index in oval cells treated with TGF-β (1 ng/ml) with or without
pretreatment with AG1478. Apoptotic nuclei were visualized and counted as in
(B). Data are mean±SEM of six independent experiments. *P < 0.05.
Figure 3. Ligand-induced Met and EGFR phosphorylation in mouse oval cells.
(A) Mouse Metflx/flx and Met-/- oval cell lines were serum-starved and treated with
EGF (20 ng/ml) or HGF (40 ng/ml) for 10 min. Untreated cells were included as
control. Whole cell lysates were collected and used for immunoblotting with
antibodies against phosphorylated EGFR and downstream signaling molecules
(AKT, ERK 1/2). (B) Cells were cultured as in (A). Whole cell lysates were
collected for immunoprecipitation with c-Met antibody, followed by
immunoblotting with anti-phosphotyrosine (4G10) and anti-Met (sc-162)
antibodies. Mock: control IP without antibody.
Figure 4. EGF-induced protection against TGF-β-induced apoptosis in mouse
Metflx/flx and Met-/- oval cell lines. Cells were treated with 1 ng/ml TGF-β alone or
with 20 ng/ml EGF for 48 hours. Apoptotic index was measured as indicated
before. Data are mean±SEM of two independent experiments run in triplicates.
***P < 0.001. Black bars, Metflx/flx cells. White bars, Met-/- cells.
Figure 5. Comparison of the HGF-induced signalling in mouse oval cells in the
absence or presence of an EGFR tyrosine kinase inhibitor. (A) Mouse Metflx/flx
oval cell lines were serum-starved and treated with HGF (40ng/ml) for different
periods of time. Where indicated, 5 µM AG1478 was added for 30 min before
treatment. Whole cell lysates were immunoblotted with the indicated antibodies.
β-actin was used for normalization.  (B) Mouse Metflx/flx and Met-/- oval cell lines
were treated with EGF (20 ng/ml) for 10 min with or without pretreatment with
AG1478 (5 µM) and processed similarly to those in (A).
Figure 6. Effect of EGFR inhibition on HGF-induced proliferative and survival
activities in mouse oval cells. (A) DNA synthesis as determined by thymidine
incorporation in oval cells cultured for 48h with 20 ng/ml EGF or 40 ng/ml HGF
after 30 min of pretreatment with 5 µM AG1478. Data are mean±SEM of two
independent experiments run in triplicates. **P < 0.01. Black bars, Metflx/flx cells.
White bars, Met-/- cells. (B) Apoptotic index in oval cells treated with 1 ng/ml TGF-
β alone or with 40 ng/ml HGF for 24h with or without pretreatment with 5 µM
AG1478. Apoptotic nuclei were visualized and counted as in figure 2B and 2D.
Data are mean±SEM of two independent experiments run in triplicates. ***P <
0.001. Black bars, Metflx/flx cells. White bars, Met-/- cells.
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Supplementary material and methods
siRNA knockdown assays
For transient siRNA transfection, cells were seeded at 50-60% confluence. On
the following day, cells were transfected with the mouse EGFR SMARTpool
siRNA (50nM) or the control non-targeting siRNA (50nM) (Dharmacon,
Lafayette, CO) using TransIT-siQuest (Mirus, Madison, WI) according to
manufacturer´s instructions. The transfected cells were grown for 16h in
complete medium, then trypsinized, diluted to the appropriate cell density, and
replated in dishes for subsequent assays, including western blotting, thymidine
incorporation into DNA as a parameter for cell proliferation, and propidium
iodide staining for apoptosis measurement.
Legend for Supplementary figure 1. Effect of targeted silencing of EGFR
expression on HGF-induced signalling, proliferative and survival activities in
mouse oval cells. (A) EGFR knockdown efficiency determined by western blot
analysis.  Mouse Metflx/flx oval cell lines were transfected with either non-
targeting negative control siRNA (si NT) or EGFR targeting siRNA (si EGFR).
Cells were then reseeded in 60mm culture dishes for western blot analysis,
serum-starved and treated with EGF (20ng/ml) for 10 min. Whole cell lysates
were immunoblotted with the indicated antibodies. β-actin was used for
normalization. (B) HGF-induced signalling in EGFR knockdown Metflx/flx oval
cells (si EGFR) as compared to control cells transfected with non-targeting
siRNA (si NT). Cells were transfected, cultured and processed as in (A), except
that they were treated with HGF (40ng/ml) for 15 min. (C) DNA synthesis as
determined by thymidine incorporation in non-targeting siRNA-transfected
(black bars) and EGFR targeting siRNA-transfected Metflx/flx oval cells (stripe-
filled bars). Cells were either left untreated (-) or treated with 20ng/ml EGF
(EGF) or 40ng/ml HGF (HGF). (D) Apoptotic index in non-targeting siRNA-
transfected (black bars) and EGFR targeting siRNA-transfected Metflx/flx oval
cells (stripe-filled bars). Cells were either left untreated (-) or treated with 1ng/ml
TGF-β (Tβ) alone or with 40ng/ml HGF (HGF+Tβ). In C and D, data are
mean±SEM of two independent experiments run in quadruplicates. ***P < 0.001
(both NT and EGFR siRNAs data sets).
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